Penumbra, Inc. Common Stock (PEN)

As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9 billion acquisition of Penumbra, Inc. (NYSE:PEN), a deal that represents the company's largest M&A move in

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of

The financial landscape of 2026 has been marked by a return to high-stakes deal-making and intense market fluctuations, and no institution seems more equipped to navigate this era than Bank of America (NYSE:BAC). On April 15, 2026, the banking giant reported a blockbuster first-quarter earnings beat, signaling a decisive

The medical technology landscape witnessed a seismic shift on Tuesday as Avanos Medical (NYSE: AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. The deal marks a significant turning point

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Penu...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

NEW YORK — The global mergers and acquisitions (M&A) market has entered a period of unprecedented expansion in the first half of 2026, marking a definitive end to the "deal desert" of previous years. Driven by a surge in private equity confidence—now reaching a staggering 86%—and a landmark

The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided the market with a compelling case study in strategic resilience. Reporting its third-quarter fiscal 2026 results, the company showcased

While the broader market has struggled with the S&P 500 down 3.2% since September 2025, Penumbra has surged ahead as its stock price has climbed by 32.3% to ...

The global mergers and acquisitions (M&A) market has roared back to life in the first quarter of 2026, shattering expectations and signaling a definitive end to the dealmaking drought of previous years. As of late March, total announced deal volume has surged past the $1 trillion milestone, a 27%

As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic $813.3 billion, a massive 50% increase over the same period last year. This record-breaking figure

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making

The U.S. Mergers and Acquisitions (M&A) landscape has entered a blistering new phase of activity, shaking off the volatility of the mid-2020s to reach levels of engagement not seen in over half a decade. Driven by a historic flood of "dry powder" and a rapidly stabilizing macroeconomic environment,

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Medical device company Penumbra (NYSE:PEN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 22.1% year on year to $385.4 million. Its non-GAAP profit of $1.18 per share was 6.1% above analysts’ consensus estimates.

In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third fiscal quarter of 2026. On February 17, 2026, the Dublin-based medical device giant announced total revenue of $9.017 billion,

On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.